Wu Jinna, Xia Cong, Liu Can, Zhang Qianshi, Xia Chenglai
Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine, Department of Pharmacy, Guangdong Engineering Research Center of Oral Restoration and Reconstruction, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou, China.
Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Front Pharmacol. 2023 Aug 23;14:1265136. doi: 10.3389/fphar.2023.1265136. eCollection 2023.
The human gut microbiota is a complex ecosystem regulating the host's environmental interaction. The same functional food or drug may have varying bioavailability and distinct effects on different individuals. Drugs such as antibiotics can alter the intestinal flora, thus affecting health. However, the relationship between intestinal flora and non-antibiotic drugs is bidirectional: it is not only affected by drugs; nevertheless, it can alter the drug structure through enzymes and change the bioavailability, biological activity, or toxicity of drugs to improve their efficacy and safety. This review summarizes the roles and mechanisms of antibiotics, antihypertensive drugs, nonsteroidal anti-inflammatory drugs, lipid-lowering drugs, hypoglycemic drugs, virus-associated therapies, metabolites, and dietary in modulating the colorectal cancer gut microbiota. It provides a reference for future antitumor therapy targeting intestinal microorganisms.
人类肠道微生物群是一个调节宿主与环境相互作用的复杂生态系统。相同的功能性食品或药物对不同个体可能具有不同的生物利用度和不同的影响。抗生素等药物会改变肠道菌群,从而影响健康。然而,肠道菌群与非抗生素药物之间的关系是双向的:它不仅受药物影响;尽管如此,它还可以通过酶改变药物结构,改变药物的生物利用度、生物活性或毒性,以提高其疗效和安全性。本综述总结了抗生素、抗高血压药物、非甾体抗炎药、降脂药物、降糖药物、病毒相关疗法、代谢物和饮食在调节结直肠癌肠道微生物群中的作用和机制。它为未来针对肠道微生物的抗肿瘤治疗提供了参考。
Front Pharmacol. 2023-8-23
Drug Metab Rev. 2020-3-2
Front Pharmacol. 2021-9-30
Biomed Pharmacother. 2022-11
Front Microbiol. 2023-2-20
Med Res Rev. 2022-1
Front Pharmacol. 2023-4-17
MedComm (2020). 2023-2-26
Mol Cancer. 2023-3-2
Lancet Diabetes Endocrinol. 2023-4